(Total Views: 159)
Posted On: 03/15/2019 4:45:41 PM
Post# of 51890
$AMGN News Article - Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke https://marketwirenews.com/news-releases/amge...50678.html
(0)
(0)
My Twitter: WhyteStocks
